Minna T.
- Country
- Finland
- Department
- Oncology
Research Overview
- Study of Inavolisib with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2‑Positive PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer
- Early Access Study of Zongertinib for the Treatment of Cancer in Patients Eligible for Anticancer Therapy
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
Data & Insights
Has run more than one trial at 284 of 536 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in advancing treatments for various forms of breast cancer, with particular emphasis on hormone receptor-positive (HR+) and HER2-negative breast cancer. Their research encompasses both early-stage and advanced disease states.
- Advanced/Metastatic Breast Cancer
- Triple Negative Breast Cancer
- Hormone Receptor-Positive Disease
- HER2-Positive Disease Management
The investigator explores novel therapeutic combinations including targeted therapies and endocrine treatments.
Prostate Cancer Studies
The investigator conducts research in metastatic castration-resistant prostate cancer (mCRPC), focusing on innovative therapeutic approaches and novel drug development.
- Advanced Prostate Cancer Treatment
- Novel Therapeutic Agents
- Targeted Radiotherapy Approaches
Their work includes evaluation of new compounds and treatment modalities for resistant disease states.
Additional Oncology Focus
The investigator's expertise extends to other areas of oncology, including hepatocellular carcinoma and broader applications in advanced cancers.
- Liver Cancer Research
- Advanced Cancer Treatment
- First-in-Human Studies
Their research includes evaluation of targeted anti-cancer drugs across multiple tumor types.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.